Company news
Soleno Therapeutics, Inc. news in 2019
Soleno Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results
November 12, 2019
Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock
October 24, 2019
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
October 22, 2019
Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
October 1, 2019
Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome
September 23, 2019
Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
September 18, 2019